Stratos Wealth Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-15,814
Closed -$545K 525
2022
Q1
$545K Buy
+15,814
New +$559K 0.04% 363

Other funds holding IDNA

Stratos Wealth Advisors's IDNA Position: Q2 2022 in Review

Stratos Wealth Advisors sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2022, closing a stake of 15,814 shares — an estimated $545K sold.

Stratos Wealth Advisors first reported a position in IDNA in Q1 2022 and held it in 1 quarter. The position peaked at $545K in Q1 2022. 73 funds tracked by Wall St. Rank hold IDNA as of Q2 2022.

  • Stratos Wealth Advisors reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q2 2022 after selling out during the quarter.
  • Stratos Wealth Advisors sold 15,814 iShares Genomics Immunology and Healthcare ETF shares in Q2 2022, an estimated $545K.
  • Stratos Wealth Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2022 and held it in 1 quarter.
  • Stratos Wealth Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $545K in Q1 2022.
  • 73 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2022.

Based on Stratos Wealth Advisors's 13F filing for Q2 2022, filed 22 Jul 2022.